News & Insights
Stay up-to-date on recent industry trends, our independent insights, press releases, and much more.
Will the UK–US Pharmaceuticals Deal Really Cause 229,000 Excess Deaths?
In this publication, we provide a critical appraisal of the 2026 BMJ article by Cross and colleagues that estimated that the 2025 UK-US trade deal on pharmaceuticals would result in 229,000 excess deaths by 2036.
The Financial Superstorm Coming for the Pharma Industry
The business of developing new medicines and bringing them to market has never been more challenging – and there’s no relief in sight.
Medicare for All
Better understand the Medicare for All Act of 2025 which would provide free universal healthcare coverage for all U.S. residents.
Potential 340B Transformation
Learn more about the proposed rule that would revise the Medicare Hospital Outpatient Prospective Payment System.
Most-Favored-Nation Pricing Meets Joint Clinical Assessment
In this publication from the Journal of Comparatvive Effectiveness Research, we review the compounding pressure on European drug launches.
340B Modifier
Here we will dissect the analysis of 340B modifier usage that was written by ADVI and Aery Policy and Access Partners.
Strategic Launch Sequencing
In this article, we will the review the background and new challenges that the Biopharma industry faces in new product launch sequencing.
PBM Reforms and FTC Settlements
Pharma companies need to begin now to strategically plan for 2028–2029 implementation of PBM reforms.
CMMI MFN Demos: Key Strategic Manufacturer Questions (Part Four)
In the final post of our series, we’ll outline some of the key strategic questions that manufacturers must address.
CMMI MFN Demonstration Projects: Globe & Guard (Part 3)
In part three of our series, we explore the effects of the Globe and Guard CMMI MFN demonstration projects and their link to Medicare drug prices.